Jacobs Levy Equity Management, Inc Revance Therapeutics, Inc. Transaction History

Jacobs Levy Equity Management, Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.34 - $4.73 $190,894 - $385,868	81,579 New	81,579 $209,000
Q4 2022 Feb 14, 2023	SELL	$18.32 - $30.66 $14.6 Million - $24.4 Million	-794,454 Reduced 86.52%	123,821 $2.29 Million
Q3 2022 Nov 15, 2022	BUY	$14.33 - $28.47 $12.2 Million - $24.3 Million	854,755 Added 1345.65%	918,275 $24.8 Million
Q2 2022 Aug 15, 2022	SELL	$11.52 - $20.4 $33,765 - $59,792	-2,931 Reduced 4.41%	63,520 $878,000
Q1 2022 May 16, 2022	SELL	$12.36 - $20.31 $2.09 Million - $3.43 Million	-169,073 Reduced 71.79%	66,451 $1.3 Million
Q4 2021 Feb 14, 2022	BUY	$12.46 - $27.87 $2.93 Million - $6.56 Million	235,524 New	235,524 $3.84 Million
Q1 2020 May 15, 2020	SELL	$12.46 - $27.81 $812,092 - $1.81 Million	-65,176 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$11.66 - $20.15 $2.12 Million - $3.67 Million	-182,115 Reduced 73.64%	65,176 $1.06 Million
Q3 2019 Nov 14, 2019	BUY	$10.22 - $14.5 $86,297 - $122,438	8,444 Added 3.54%	247,291 $3.22 Million
Q2 2019 Aug 13, 2019	BUY	$10.67 - $15.49 $2.55 Million - $3.7 Million	238,847 New	238,847 $3.1 Million

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.